| HOME >> BIOLOGY >> TECHNOLOGY |
Research and
development 7,288,460 2,678,749 20,554,105 9,214,759
Selling, general and
administrative 3,946,050 2,374,984 11,155,194 6,912,853
Total Operating
Expenses 11,263,739 5,095,132 31,949,728 16,564,602
LOSS FROM OPERATIONS (9,925,830) (4,668,805) (28,150,207) (15,582,856)
Interest income 1,217,439 290,842 4,254,024 830,870
NET LOSS $(8,708,391) $(4,377,963) $(23,896,183) $(14,751,986)
Basic and diluted net
loss per share $(0.11) $(0.07) $(0.32) $(0.24)
Shares used in computing
net loss per share,
basic and diluted 77,459,803 65,402,770 74,317,930 62,610,265
HALOZYME THERAPEUTICS, INC.
CONSOLIDATED BALANCE SHEETS
AS OF DECEMBER 31, 2007 AND 2006
2007 2006
ASSETS:
Cash and cash equivalents $97,679,085 $44,189,403
Accounts receivable 779,825 363,565
Inventory 703,468 442,492
Prepaid expenses and other assets 2,014,680 598,090
Total current assets 101,177,058 45,593,550
Property and equipment, net 2,283,316 497,770
Total Assets $103,460,374 $46,091,320
LIABILITIES AND STOCKHOLDERS' EQUITY:
Accounts payable $3,055,637 $2,017,395
Accrued expenses 2,502,259 1,011,153
Deferred revenue 3,306,225 1,221,992
Total current liabilities 8,864,121 4,250,540
'/>"/>
| SOURCE Halozyme Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved |